Shire thinks it can beat rare-disease rivals; AZ hires JP Morgan for Astra Tech sale;

  @FiercePharma: Moody's repeats gloomy view of pharma industry. Article | Follow @FiercePharma

Special Report: Pharma's Biggest Flops. Report 

Special Report: Top 10 Medical Device Companies: 2010. Report 

> Shire believes its record in developing medicines to treat rare diseases, mostly affecting one in 100,000 people or fewer, will help it maintain a lead over bigger rivals that are targeting the sector. News

> AstraZeneca confirmed that it was considering spinning off Astra Tech and had hired JP Morgan Chase (JPM.N) to help with a strategic review of the dental implants and medical devices unit. Report

> A West Virgnia appeals court reversed a $4.5 million judgment against Johnson & Johnson in which the state attorney general charged doctors were misled about risks and benefits of its Risperdal antipsychotic and Duragesic pain patch. Article

> European regulators adopted a new guideline on so-called biosimilar antibody drugs, paving the way for cheaper copies of multi-billion-dollar medicines for cancer and other serious diseases. Item

> Johnson & Johnson's Tibotec unit and the U.S. government separately sued Mylan and Lupin to prevent sales of a generic version of the HIV medicine Prezista. Story

> IMS Health predicts China will become the world's second largest pharmaceutical market by 2015 due to robust economic growth and healthcare reforms that allow for increased spending on drugs. Report

> Doctors are putting pressure on the U.K. government to seal a legal loophole that allows drugmakers to license existing therapies as orphan drugs and then charge exorbitant prices for them. News

> The European Medicines Agency said it was recommending approval for wider use of Sanofi-Aventis (SASY.PA) and Bristol-Myers Squibb's (BMY.N) blood thinner Plavix. Story

Biotech News

  @FierceBiotech: Genzyme restructuring moves forward with sale of diagnostic ops. Report | Follow @FierceBiotech

 @JohnCFierce: Interesting factoid: Bloomberg says that biotech buyers paid a median of 1.37 times market value over the past 5 years. Roche paid 1.25 for Genentech. |  Follow @JohnCFierce

> Bleeding forces Pfizer, BMS to halt apixaban study. News

> Bionor stock skyrockets on unexpected HIV vax results. Report 

> FDA approves Xgeva (denosumab) for oncology indication. Item

> Spectrum sues Cangene for breach of contract. Article

> EU adopts new biosimilar guideline. Report

> BTG buys rival for $242M. Story

And Finally... Europe's drug regulator will make thousands of pages of clinical trial reports public next week after pressure from drug-safety activists. Report

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.